

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**June 2020**

---

**Commission File Number:** 0001723069

---

**Tiziana Life Sciences plc**

(Exact Name of Registrant as Specified in Its Charter)

---

**3<sup>rd</sup> Floor,  
11-12 St James's Square  
London SW1Y 4LB  
United Kingdom**

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On June 23, 2020, Tiziana Life Sciences plc (the “Company”) issued a regulatory news service announcement in the United Kingdom announcing the Annual General Meeting (the “RNS Announcement”).

The RNS Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**TIZIANA LIFE SCIENCES PLC**

Date: June 23, 2020

By: /s/ Kunwar Shailubhai

Name: Kunwar Shailubhai

Title: Chief Executive Officer

EXHIBIT INDEX

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Regulatory News Service Announcement, dated June 23, 2020</a>

**Tiziana Life Sciences plc**  
**(“Tiziana” or the “Company”)**

**Annual General Meeting**

London, New York, 23 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it will hold its annual general meeting (“AGM”) on 16 July 2020 at 10.00am.

The Notice of AGM, together with Proxy Form and the Annual Report and Accounts for the year ended 31 December 2019, will be posted to shareholders today. The Notice of AGM will shortly also be available on the Company’s website: [www.tizianalifesciences.com](http://www.tizianalifesciences.com).

Please note that arrangements for the AGM this year are different from the usual public company in-person format. As we expect significant restrictions on personal movement to still be in place due to Covid-19, we are utilizing the provisions in our recently adopted articles of association, which allow for the holding of the meeting virtually, on an electronic platform. Accordingly, this year’s AGM will be an electronic meeting only. All voting at the resolutions at the AGM will be conducted on a poll (a requirement of our recently adopted articles of association) which means that you should submit your proxy (by post or, preferably, online voting) as soon as possible. We ask that, where possible, questions which shareholders wish to raise be submitted to [info@tizianalifesciences.com](mailto:info@tizianalifesciences.com) in advance.

The platform that we will be using will allow shareholders the option to submit a separate poll card at the electronic meeting but, to ease administration, we request that proxies be lodged in advance wherever possible.

Full details of the operation and arrangements for the AGM are set out in the Notice of AGM.

**About Tiziana Life Sciences**

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

**For further enquiries:**

<b>Tiziana Life Sciences plc</b> Gabriele Cerrone, Chairman and founder	+44 (0)20 7495 2379
<b>Cairn Financial Advisers LLP (Nominated adviser)</b> Liam Murray / Jo Turner	+44 (0)20 7213 0880
<b>Optiva Securities Limited (Broker)</b> Robert Emmet	+ 44 (0)20 3981 4173